Hyoscine%2525252520butyl%2525252520bromide

# Hyoscine butylbromide ## Overview Hyoscine butylbromide (scopolamine butylbromide) is a quaternary ammonium antispasmodic agent. Unlike its tertiary amine counterpart (hyoscine hydrobromide), it has poor blood-brain barrier penetration, resulting in minimal central nervous system effects (e.g., sedation). ## Primary Indications - Symptomatic relief of gastrointestinal (GI) and genitourinary (GU) spasms. - Irritable bowel syndrome (IBS). - Palliative care (reduction of excessive respiratory secretions/death rattle). ## Adult Dosing - **Oral:** 10 mg to 20 mg three to four times daily. Maximum: 100 mg/day. - **Intramuscular (IM)/Intravenous (IV):** 20 mg as a single dose, repeated every 30 minutes if necessary. Maximum: 100 mg/day. ## Pediatric Dosing *Note: Palliative dosing protocols vary by institution; always consult local pediatric guidelines.* - **Children (6–12 years):** 10 mg orally three times daily. - **Palliative Care (off-label):** Generally weight-based; often started at 0.2–0.3 mg/kg/dose every 4–8 hours via subcutaneous infusion or intermittent bolus. ## Dose Adjustments - **Renal/Hepatic Impairment:** No formal standardized adjustments; however, use caution and monitor for anticholinergic accumulation in severe impairment. - **Elderly:** Increased risk of urinary retention and tachyarrhythmia; use lower initial doses and closely monitor. ## Contraindications - Myasthenia gravis. - Megacolon. - Narrow-angle glaucoma. - Mechanical stenosis of the GI tract or paralytic ileus. - Tachycardia/tachyarrhythmia. ## Adverse Effects - **Common:** Dry mouth, tachycardia, blurred vision (mydriasis), and constipation. - **Serious:** Urinary retention, anaphylaxis/hypersensitivity, and increased intraocular pressure. ## Key Drug Interactions - **Anticholinergics:** Additive risk of side effects (e.g., TCAs, antihistamines, antipsychotics). - **Metoclopramide:** Antagonistic effects on GI motility; avoid concurrent use. - **Tachycardia-inducing agents:** May worsen drug-induced tachycardia. ## Monitoring - Heart rate and rhythm (especially in patients with underlying cardiac history). - Voiding patterns (risk of urinary retention). - Assessment of abdominal pain or spasticity relief. - In palliative settings: Assessment of secretion reduction (e.g., "death rattle" intensity). ## Clinical Pearls - **Administration:** IV administration can cause transient tachycardia; infuse slowly. - **CNS Profile:** Because it is a quaternary ammonium compound, it does NOT cause typical anticholinergic CNS side effects like confusion or sedation, making it safer for the elderly than atropine or procyclidine in certain settings. - **Absorption:** Oral absorption is low (less than 10%); systemic bioavailability is significantly improved via the parenteral route. - **Warning:** Do not administer to patients with suspected or confirmed cardiac arrhythmias unless benefits outweigh risks. *** *Disclaimer: This information is for educational purposes only. Drug dosing and clinical protocols can vary by region and institution. Always verify specific dosages, contraindications, and drug-drug interactions using institutional guidelines or official prescribing information (such as the BNF or local formulary) before prescribing or administering medication.*